Detail akcie AB Science online

Business Summary: AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
Financial Summary: BRIEF: For the six months ended 30 June 2024, AB Science SA revenues increased 25% to EUR560K. Net loss decreased 57% to EUR4.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development expenses decrease of 64% to EUR2.6M (expense), Other Financial Expenses decrease of 63% to EUR610K (expense).